- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00958516
Assessment of the Phototoxic Potential of LEO 29102 Cream
October 24, 2013 updated by: LEO Pharma
A Phase 1 Study Evaluating the Phototoxic Potential of LEO 29102 Cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g) and the Cream Vehicle, Applied on Intact Skin of Healthy Male Subjects
The purpose of this trial is to evaluate the phototoxic potential of a single application on healthy skin of LEO 29102 cream in different doses.
Study Overview
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
St Quentin en Yvelines Cedex, France, 78054
- LEO Pharma site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Subjects having understood and signed an informed consent form
- Male adults between the age of 18 and 65 years (both inclusive)
- Healthy subjects without signs of skin irritation on test areas (erythema, dryness, roughness or scaling)
- Subjects willing and able to follow all the study procedures and complete the whole study
- Subjects affiliated to a social security system
Exclusion Criteria:
- Females
- Males who are not willing to use a local contraception for the entire duration of the study, and refrain from fathering a child within 3 months following the study drug
- Systemic treatments which may interfere with the inflammatory reaction (e.g., corticosteroids and other anti-inflammatory drugs) within 2 weeks prior to randomisation
- Systemic or topical treatments suspected of causing photobiological reactions (e.g., tetracycline, thiazides, fluoroquinolones) within 4 weeks prior to randomisation
- Exposure to excessive or chronic UV radiation (i.e., sunbathing, solarium, phototherapy) within 4 weeks prior to inclusion or is planned during the study period
- Dark pigmentation of the skin or skin type that may, in any way, confound interpretation of the study results (skin types V and VI on the Fitzpatrick scale)
- Scars, moles, sunburn or other blemishes in the test area which may interfere with grading
- Any systemic or cutaneous disease on the test area that may confound interpretation of the study results (e.g., atopic dermatitis, eczema, psoriasis)
- Relevant history of or concurrent photo-induced or photo-aggravated disease (abnormal response to sunlight
- Subjects with a history of serious allergy, allergic skin rash or known sensitivity to any component of the investigational products
- Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within the last four (4) weeks before randomisation
- Participation in any other current interventional clinical trial based on interview of the subject
- Previously randomised in this trial
- Subjects impossible to contact in case of emergency
- Subjects known or, in the opinion of the investigator, are unlikely to comply with the Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state)
- Subjects who are in an exclusion period in the National Biomedical Research Register of the French Ministry of Health
- Subjects under guardianship, hospitalised in a public or private institution for a reason other than research or subject deprived of freedom
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LEO 29102 cream
|
LEO 29102 cream in different doses and the cream vehicle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phototoxic reaction according to the investigator's assessment
Time Frame: 5 days
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical scoring and other skin reactions
Time Frame: 5 days
|
5 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Director International Clinical Development, MD, LEO Pharma
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
August 12, 2009
First Submitted That Met QC Criteria
August 12, 2009
First Posted (Estimate)
August 13, 2009
Study Record Updates
Last Update Posted (Estimate)
October 25, 2013
Last Update Submitted That Met QC Criteria
October 24, 2013
Last Verified
October 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LEO 29102-C02
- EudraCT Number 2009-011177-32
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on LEO 29102 cream
-
LEO PharmaCompletedAtopic DermatitisNetherlands
-
LEO PharmaTerminatedAtopic DermatitisGermany
-
LEO PharmaCompleted
-
LEO PharmaCompleted
-
LEO PharmaCompletedAtopic DermatitisUnited Kingdom
-
LEO PharmaCompleted
-
LEO PharmaTerminatedDiscoid Lupus ErythematosusUnited States, France, Germany, Denmark
-
LEO PharmaCompletedChronic Hand EczemaUnited States, Germany, Denmark
-
LEO PharmaCompletedHealthy VolunteersGermany
-
LEO PharmaCompletedAtopic DermatitisUnited States, Canada, Australia